Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Serina Therapeutics (SER) over the last 7 years, with Q3 2025 value amounting to $350000.0.

  • Serina Therapeutics' Other Accumulated Expenses rose 7676.77% to $350000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $350000.0, marking a year-over-year increase of 7676.77%. This contributed to the annual value of $193000.0 for FY2024, which is 2280.0% down from last year.
  • As of Q3 2025, Serina Therapeutics' Other Accumulated Expenses stood at $350000.0, which was up 7676.77% from $545000.0 recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' Other Accumulated Expenses peaked at $545000.0 during Q2 2025, and registered a low of $5000.0 during Q2 2024.
  • In the last 4 years, Serina Therapeutics' Other Accumulated Expenses had a median value of $193000.0 in 2024 and averaged $209727.3.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 9782.61% in 2024, then surged by 1080000.0% in 2025.
  • Quarter analysis of 4 years shows Serina Therapeutics' Other Accumulated Expenses stood at $141000.0 in 2022, then soared by 77.3% to $250000.0 in 2023, then decreased by 22.8% to $193000.0 in 2024, then surged by 81.35% to $350000.0 in 2025.
  • Its Other Accumulated Expenses was $350000.0 in Q3 2025, compared to $545000.0 in Q2 2025 and $185000.0 in Q1 2025.